Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

Phase 1 Completed 24 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.

Timeline

Start: 2010-11
Primary completion: 2011-09
Completion: 2011-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tesidolumab	Monoclonal antibody	0.15 mg	Intravitreal
Subject	tesidolumab	Monoclonal antibody	0.5 mg	Intravitreal
Subject	tesidolumab	Monoclonal antibody	1.5 mg	Intravitreal
Subject	tesidolumab	Monoclonal antibody	5 mg	Intravitreal

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

Summary

Timeline

Drugs

Indications